Holen Sie sich die Stockscreener-App
469.36
0.95%
4.41
Handel nachbörslich:
469.36
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran - simplywall.st
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock - Yahoo Finance
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutEarnings Risk Report & High Return Stock Watch Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratiosJuly 2025 Update & Safe Capital Allocation Plans - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
JP Morgan Lowers Price Target for ALNY, Maintains Overweight Rat - GuruFocus
Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Analyst Calls & Free Real-Time Market Sentiment Alerts - newser.com
What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Weekly Stock Report & Fast Moving Trade Plans - newser.com
Alnylam Pharma Secures $500M Credit Agreement - MSN
Vontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Callan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a Robust Pipeline and Strong Buy Ratings - DirectorsTalk Interviews
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Sivik Global Healthcare LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Aberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY): Valuation Snapshot Following New Phase 3 Data and Pipeline Progress - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $570 Price Target | ALNY Stock News - GuruFocus
Is Alnylam Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Using AI based signals to follow Alnylam Pharmaceuticals Inc.Trade Volume Summary & High Conviction Buy Zone Alerts - newser.com
What drives Alnylam Pharmaceuticals Inc stock priceGlobal Trade Effects & Access Risk Ratings for Every Stock - earlytimes.in
KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN
Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morg - GuruFocus
Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat
Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickWeekly Investment Recap & Smart Money Movement Tracker - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.Forecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Alnylam Pharmaceuticals Inc a good long term investmentStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring Growth Potential and Investment Risks in Biotech - DirectorsTalk Interviews
Is Alnylam Pharmaceuticals Inc DUL a good long term investmentGlobal Trade Effects & Build Wealth Brick by Brick With Us - earlytimes.in
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.Quarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After ZENITH Phase 3 Trial Launch and HELIOS-B Data Reveal - simplywall.st
Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Set To Breakeven - Yahoo Finance
AMF Tjanstepension AB Makes New $10.61 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,937 Shares of Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $4,034,094.20 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,364,372.56 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,727,283.05 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,405 Shares - MarketBeat
Alnylam Pharmaceuticals says on Sept 30, entered into credit agreement with Bank of AmericaSEC filing - MarketScreener
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
2.67%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):